STOCK TITAN

MACROGENICS (MGNX) director O'Brien receives RSUs and 22,000-share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MACROGENICS INC director Federica F. O'Brien reported equity compensation and an option exercise. On May 18, 2026, 3,750 restricted stock units vested and were exercised into 3,750 shares of common stock, leaving her with 14,750 common shares directly owned.

On May 19, 2026, she received a grant of 3,750 new restricted stock units and a stock option for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. The option vests in monthly 1/12th increments, while the new RSUs vest one year from grant or the day prior to the next annual meeting, if earlier. These are compensation-related awards, not open-market purchases.

Positive

  • None.

Negative

  • None.
Insider O'Brien Federica F.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 22,000 $0.00 --
Grant/Award Restricted Stock Unit 3,750 $0.00 --
Exercise Restricted Stock Unit 3,750 $0.00 --
Exercise Common Stock 3,750 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 22,000 shares (Direct, null); Restricted Stock Unit — 3,750 shares (Direct, null); Common Stock — 14,750 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
RSUs vested into shares 3,750 shares RSUs vested and converted to common stock on May 18, 2026
Common shares held after vesting 14,750 shares Direct MACROGENICS common stock ownership after May 18, 2026
New RSU grant 3,750 units Restricted stock units granted on May 19, 2026
New stock option grant 22,000 shares Stock option for MACROGENICS common stock granted May 19, 2026
Option exercise price $4.52 per share Exercise price of 22,000-share stock option expiring May 19, 2036
Restricted Stock Unit financial
"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSUs financial
"The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (right to buy) financial
"Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 4.5200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting of Stockholders financial
"one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Brien Federica F.

(Last)(First)(Middle)
9704 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026M3,750A(1)14,750D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0(1)05/18/2026M3,750 (2) (2)Common Stock3,750$00D
Stock Option (right to buy)$4.5205/19/2026A22,000 (3)05/19/2036Common Stock22,000$022,000D
Restricted Stock Unit$0(1)05/19/2026A3,750 (4) (4)Common Stock3,750$03,750D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
2. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
3. The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
4. The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
Remarks:
Beth A. Smith, Attorney-in-fact05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did MACROGENICS (MGNX) director Federica O'Brien report?

Federica O'Brien reported an equity grant and an option exercise. 3,750 restricted stock units vested into 3,750 common shares, and she received 3,750 new RSUs plus a 22,000-share stock option as director compensation.

How many MACROGENICS (MGNX) shares does Federica O'Brien hold after these transactions?

After the reported transactions, Federica O'Brien directly owns 14,750 shares of MACROGENICS common stock. This reflects the 3,750 RSUs that vested into shares on May 18, 2026, as shown in the Form 4 filing data.

What are the terms of Federica O'Brien’s new MACROGENICS stock option grant?

She received a stock option for 22,000 shares of MACROGENICS common stock at an exercise price of $4.52 per share, expiring May 19, 2036. The option vests in monthly cumulative 1/12th increments starting one month after the grant date.

When do Federica O'Brien’s new MACROGENICS restricted stock units vest?

The new restricted stock units granted to Federica O'Brien will vest one year after the grant date or on the day prior to the next annual meeting of stockholders, if that meeting occurs earlier, according to the Form 4 footnote.

Were Federica O'Brien’s MACROGENICS transactions open-market purchases or sales?

The reported activity reflects equity compensation and an option exercise, not open-market trading. RSUs vested into common shares and she received grants of new RSUs and a stock option as part of her director compensation package.

What does the RSU vesting on May 18, 2026 mean for MACROGENICS (MGNX) director ownership?

On May 18, 2026, 3,750 RSUs vested for Federica O'Brien, converting into 3,750 common shares. This increased her directly held MACROGENICS common stock to 14,750 shares, as reported in the Form 4 filing.